Effect of preoperative Mg sulfate infusion on serum cardiac troponin (cTn) in moderate preeclamptic undergoing elective cesarean section under spinal anesthesia  by Elzayyat, Nashwa S. & Yacoub, Marium H.
Egyptian Journal of Anaesthesia (2014) 30, 299–303Egyptian Society of Anesthesiologists
Egyptian Journal of Anaesthesia
www.elsevier.com/locate/egja
www.sciencedirect.comResearch ArticleEﬀect of preoperative Mg sulfate infusion
on serum cardiac troponin (cTn) in
moderate preeclamptic undergoing elective
cesarean section under spinal anesthesia* Corresponding author. Address: Cairo University, Anesthesia, 12
ahmed mokhtar hegazy manial elroda, Cairo, Egypt. Tel.: +20
1222394934.
E-mail address: nanosami@yahoo.com (N.S. Elzayyat).
Peer review under responsibility of Egyptian Society of Anesthesiol-
ogists.
Production and hosting by Elsevier
1110-1849 ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
Open access under CC BY-NC-ND license. http://dx.doi.org/10.1016/j.egja.2014.01.006
Open access under CC BY-NC-NNashwa S. Elzayyat a,*, Marium H. Yacoub ba Department of Anesthesia, Cairo University, Egypt
b Department of Clinical Pathology, Cairo University, EgyptReceived 13 December 2013; revised 13 January 2014; accepted 17 January 2014
Available online 7 February 2014KEYWORDS
Magnesium sulfate;
Preeclampsia;
TroponinAbstract This study was designed to investigate and compare the effect of preoperative Mg sulfate
infusion on serum cardiac troponin (cTn) in moderate preeclampsia undergoing elective cesarean
section. A total of ﬁfty parturients having moderate preeclampsia scheduled for elective cesarean
section were included. They were randomly allocated into two equal groups 25 each, magnesium
group (GMg) received preoperative magnesium sulfate infusion and control group (GC) then both
received spinal anesthesia, serum troponin measured preoperative then at 6, 12 and 24 h postoper-
ative. Mean arterial pressure and heart rate were also recorded. Baseline serum cardiac troponin
was higher above normal and was comparable at the rest of times in both groups. Mean arterial
pressure readings were signiﬁcantly lower in GMg compared to GC at induction of spinal, skin inci-
sion and skin closure (P< 0.05) and were comparable at the rest of times. Serum cardiac troponin
(cTn) levels were comparable in parturients received magnesium sulfate infusion preoperatively with
those did not receive magnesium sulfate.
ª 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.D license.1. Introduction
Hypertensive disorders occur as a complication of approxi-
mately 5–8% of all pregnancies, and preeclampsia represents
50–60% of these disorders. All have serious effects on both
maternal and fetal mortality and morbidity [1].
Pre-eclampsia is a multi-system disease and the main pathol-
ogy is capillary damage and vasospasm. Moderate preeclamp-
sia is diagnosed according to the criteria recommended by
American college of Obstetrics and Gynecology (ACOG):
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measured in two opportunities 6 h apart plus proteinuria (+1
or +2 on dipstick). Proteinuria is deﬁned as a concentration
of at least 30 mg/dl (at least 1+ on dipstick) in at least two
random urine samples collected at least 6 h apart. In severe
preeclampsia pulmonary edema can develop due to high left
ventricular ﬁlling pressure, also can progress with seizures [2].
Cardiac troponin (cTn) is an inhibitory protein complex
located on the actin ﬁlament in all striated muscles and consists
of three submits T, I, and C and it coordinates striated muscle
contraction in response to voltage charges. Cardiac troponin I
is encoded by speciﬁc genes, and blocks the formation of
actin-myosin bridges and since it is not found in skeletal
muscles, it is considered a highly speciﬁc indicator ofmyocardial
injury in adults [3].
It is reported that troponin measurement has a great value
in the diagnosis of diseases with myocardial damage as ische-
mic heart disease, hypertension, preeclampsia, cardiac trauma;
congestive heart failure, hypotension, chronic renal failure,
myocarditis, sepsis, amyloidosis, and pulmonary embolism.
It has also been suggested that as this damage is frequently
seen in practice and there is a signiﬁcant relationship between
cardiac troponin levels and the severity of disease, the impor-
tance of troponin tests is increased [4].
The vasodilator effect of MgSO4 has been investigated both
in vivo and in vitro animal studies which have shown that it is
a vasodilator of large arteries as the aorta [5], as well as smaller
vessels including mesenteric [6], skeletal muscle [7] uterine [8],
and cerebral arteries [6].
Magnesium may act by stimulating production of prostacy-
clin by endothelial cells causing vasodilatation, or by inhibiting
platelet aggregation [9]. In patients with pregnancy-induced
hypertension, MgSO4 treatment signiﬁcantly decreases circu-
lating levels of angiotensin-converting enzyme [10]. These ac-
tions may inhibit the endothelial dysfunction associated with
preeclampsia [11].
Magnesium ions also suppress calcium inﬂux so modulating
cardiovascular cell function. Mg2+ inhibits ion channels,
including voltage-dependent Ca2+ channels in cardiac myo-
cytes, which leads to cardio-protection via antiarrythmic ac-
tion. This action also decreases cell injury and cell death due
to ischemia [12].
Aim of the study: was to compare the effect of Mg sulfate
given preoperative on cardiac troponin I to parturients with
moderate preeclampsia undergoing elective cesarean section.
2. Patients and methods
After the approval of institutional ethical committee and
obtaining informed written consent, 50 full-term pregnant fe-
males (age group 25–40 years and gestational age 36–40 weeks)
having moderate pre-eclampsia scheduled for elective cesarean
section. Exclusion criteria included the following: severe pre-
eclampsia, HELLP syndrome, chronic hypertension not preg-
nancy induced, diabetes mellitus, ischemic and valvular heart
disease, infections at puncture site contraindicating spinal
anesthesia, renal or hepatic diseases affection with preeclamp-
sia, coagulopathies, and known allergy to any of the studied
drugs. The study performed from January 2013 to July 2013
in the new obstetric and gynecology hospital-Kasr ELAini.Parturients were randomly allocated by closed envelops to
two groups.
Control group (G C) (n= 25): parturients with moderate
preeclampsia did not receive Mg sulfate.
Study group (G Mg) (n= 25): parturients with moderate
preeclampsia received Mg sulfate.
3. Protocol for magnesium sulfate administration in the study
Half an hour preoperatively, a loading dose of 4 g MgSO4 was
infused over 15–20 min. This is then followed by a continuous
infusion of 1 g/h for 24 h post-operative. The target plasma
concentration should be between 2 and 3.5 mol/l and magne-
sium sulfate toxicity was monitored by urine output, deep ten-
don reﬂexes, respiratory rate and serum magnesium levels and
managed with an infusion of 10 ml of 10% calcium gluconate
and cessation of magnesium infusion.4. Preoperative preparation
Systolic and diastolic blood pressure, ECG and echocardio-
gram were assessed, coagulation proﬁle including prothrom-
bin time, activated partial thromboplastin time, platelet,
serum glucose, creatinine, Na, K, Ca, ALT, AST, and total
bilirubin were all reviewed. All medications were given at
the time. Half an hour before entering the operating room
two intravenous lines were inserted one for Mg sulfate
infusion was started, and 8 ml/kg ringer acetate was given
as a preload in the other iv line. On entering the operating
room all parturients received the routine monitors; ﬁve
leads ECG, non-invasive blood pressure monitoring and
pulse oximetry.
Spinal anesthesia was performed with the parturient sitting
and after complete sterilization, inﬁltration of the skin with
2 ml of 2% lidocaine, atraumatic spinal needle (G25) is ad-
vanced into the subarachnoid space and 0.5% heavy bupiva-
caine and 25 lg fentanyl (a total volume of 2.8 ml) was
administered. Sensory block was assessed using cold and pin-
prick perception till reach T4 sensory level. Motor blockade
assessed using modiﬁed Bromage scale.
After delivery of the fetus, Oxytocin 10 IU/L ringer acetate
given by intravenous drip. Neonatal viability is assessed by
using APGAR scoring system at 1 and 5 min post-delivery.
Hypotension is deﬁned as a decrease in systolic blood pres-
sure by 20% from baseline. It was treated by the administra-
tion of intravenous ephedrine in incremental doses of (5 mg).
Bradycardia (Heart rate <60/min) was treated by 0.02 mg/
kg atropine.
IM pethidine 50 mg was given for postoperative pain when
needed.
5. Samples collection
Venous Blood samples were collected in EDTA tubes from all
parturient before caesarian sections and magnesium sulfate
infusion, then 6, 12 and 24 h postoperative. The samples were
transported immediately to the clinical pathology laboratory
of Kasr ELAini hospital, Cairo University, where plasma
was separated by centrifugation at 2000 · g for 15 min and
Table 2 Serum cardiac troponin I (cTnI).
Time G C (n= 25) G Mg (n= 25) P value
Preoperative 0.12 ± 0.07 0.13 ± 0.08 0.975
6 h postoperative 0.11 ± 0.05 0.12 ± 0.06 0.700
12 h postoperative 0.11 ± 0.03 0.11 ± 0.05 0.206
24 h postoperative 0.10 ± 0.03 0.09 ± 0.01 0.830
Data expressed as mean ± SD, P< 0.05 considered signiﬁcant.
Table 3 Mean arterial blood pressure.
Time G C (n= 25) G Mg (n= 25) P value
Preoperative 120.7 ± 2.9 109.2 ± 1.8 <0.001
Induction of anesthesia 112.4 ± 1.6 107.4 ± 1.7 <0.001
Skin incision 117.5 ± 1.8 111.3 ± 2.4 <0.001
Skin closure 112.2 ± 1.7 107.4 ± 1.8 <0.001
1 h Postoperative 110.4 ± 1.7 108 ± 1.6 0.027
2 h Postoperative 112.4 ± 1.7 110 ± 2.9 0.07
3 h Postoperative 113.2 ± 1.5 109.8 ± 29 0.03
Data expressed as mean ± SD, P< 0.05 considered signiﬁcant.
Table 4 Heart rate (HR).
Time G C (n= 25) G Mg (n= 25)
Preoperative 95.2 ± 3.7 93.6 ± 2.6
Induction of anesthesia 97.6 ± 5.1 98.2 ± 4.2
Skin incision 104.1 ± 2.7 103.1 ± 2.1
Skin closure 103.4 ± 2.7 103.4 ± 3
1 h Postoperative 92 ± 1.7 92.2 ± 1.8
2 h Postoperative 96.8 ± 3.1 96.2 ± 3.1
3 h Postoperative 100.4 ± 4.5 101 ± 4.8
Data expressed as mean ± SD, P< 0.05 considered signiﬁcant.
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using SIEMENS Dimension clinical chemistry system Heter-
ogenous Immunoassay Module, Flex reagent cartilage, Cat.
No. RF421C. Assays for cardiac troponin-I (CTNI) is a one
step enzyme immunoassay based on the ‘‘sandwich’’ principle.
Sample is incubated with chromium dioxide particles
coated with a monoclonal antibody speciﬁc for the cardiac
troponin-I molecules, and a conjugate reagent [alkaline
phosphatase (ALP)] labeled monoclonal antibody speciﬁc for
cardiac troponin-I, to form a particle/cardiac troponin-I/
conjugate sandwich. Unbound conjugate is removed by
magnetic separation and washing. After separation and wash-
ing, the particle/cardiac troponin I/conjugate sandwich is
transferred to the cuvette where the sandwich bound ALP
triggers an ampliﬁcation cascade. ALP dephosphorylates
synthetic ﬂavin adenine dinucleotide phosphate (FADP) to
produce FAD. FAD binds to apo D-amino acid oxidase and
converts it to active holo D-amino acid oxidase. Each molecule
of holo D-amino acid oxidase then produces multiple
molecules of hydrogen peroxide (H2O2) which, in the presence
of horseradish peroxidase (HRP), convert 3,5-dichloro-
2-hydroxybenzenesulfonic acid (DCHBS) and 4-aminoantipy-
rine (4-AAP) to a colored product that absorbs at 510 nm.
The color change measured is directly proportional to the
concentration of cardiac troponin-I present in the patient
sample.
6. Statistical analysis
Data were analyzed using SPSS (SPSS 15.0, SPSS Inc, Chi-
cago, II, USA). Parametric data were expressed as mean and
standard deviation (SD) and analyzed using the independent
t test. Continuous data are compared by one-way ANOVA
or repeated measures with two-way ANOVA as a post hoc
procedure for comparisons against baseline values to further
investigate any statistically signiﬁcant ﬁndings. P values
<0.05 will be considered signiﬁcant.
7. Results
Parturients demographic and obstetric data were comparable
(Table 1)
Preoperative mean serum troponin levels were higher than
normal in both groups (0.12–0.13) ng/ml.
The mean serum cardiac troponin I (cTnI) preoperative
readings were (0.12 ± 0.07 and 0.13 ± 0.08) ng/ml, slightly
elevated above normal levels (0–0.05 ng/ml).
Serum levels of cardiac troponin I (cTnI) are summarized in
Table 2. Serum cTnI at different sampling times were com-Table 1 Demographic and obstetric.
Variable G C (n= 25) G Mg (n= 25) P value
Age (years) 30 ± 4.4 31 ± 4.8 NS
Weight (kg) 76 ± 3 75 ± 2.8 NS
Hight (cm) 158 ± 2 157 ± 4 NS
Gestation (weeks) 38 ± 1.3 37 ± 2.7 NS
Platelets 172 ± 17 177 ± 15 NS
Data expressed as mean ± SD, P< 0.05 considered signiﬁcant.pared as regards the pre-treatment with MgSO4 serum cTnI
did not showed any statistically signiﬁcant between-groups dif-
ferences at 6, 12 and 24 h postoperative (P> 0.05).
As regards pre-treatment with MgSO4; MAP values showed
signiﬁcant differences in GMg compared to GC at the time of
induction, skin incision and at skin closure (P< 0.05) (Ta-
ble 3). As regards intergroup differences between baseline
and postoperative MAP readings, no statistically signiﬁcant
data observed in both groups.
Heart rate (HR) recordings throughout the study period are
summarized in Table 4. HR recordings were comparable with
no statistically signiﬁcant differences between-group or intra-
group variability (P> 0.05).
8. Discussion
The results of the current study showed mean serum troponin
cardiac troponin I (cTnI) mildly elevated above normal levels
in all preeclamptic parturients.
This ﬁnding was consistent with the results of the study
done by Fleming and colleagues [13] who investigated serum
cardiac troponin I, a sensitive marker of cardiac myocyte dam-
age, in normal pregnancy and pregnancies complicated by
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elevated in women with hypertensive disorders of pregnancy
indicating some degree of cardiac myoﬁbrillary damage in
these disorders.
Patients with arterial hypertension have shown increased
cardiac troponin I (cTnI) level above normal limits due to sub-
clinical myocardial necrosis [14].
Contrary to these results another study by Atis et al. [15]
investigated troponin I and homocysteine in pregnant women
with severe and mild preeclampsia and concluded that Tropo-
nin I levels are not signiﬁcantly increased in either mild or se-
vere preeclampsia.
The results of the current study showed comparable levels
of serum cardiac troponin at 6, 12 and 24 h postoperative in
GMg (study) compared to GC (control) and although the ser-
um troponin was lower in (GMg) compared to GC, yet did not
reach signiﬁcant levels.
These results were contrary to Atalay and colleagues [16]
found that the serum cTnI level in the pre-eclamptic was signif-
icantly high (P< 0.01), and MgSO4 pretreatment values of
cTnI were signiﬁcantly higher compared with post-treatment
values (P< 0.01).
Also Chakraborti et al. [17] reported that hypomagnesemia
leads to progressive coronary vasoconstriction and suggested
that magnesium can be protective in many cardiovascular dis-
eases, including ischemic heart disease.
Other studies by Katus et al., showed that cTnI has a con-
sistent release pattern following myocardial injury compared
to cTnT which has a biphasic pattern after cardiac surgery
which prohibit its use in such population.
This can be explained pathophysiologically as the major
percentage of cTnT (94%) is structurally bound to the contrac-
tile apparatus of the cardiomyocyte, and a smaller amount
found as a precursor in the cytoplasm. When minor ischemic
or reperfusion occurred there is disruption and leakage of
cytosolic cTnT into the circulation [18].
In the current study, MAP values showed signiﬁcant lower
values (P< 0.05) in G Mg (study) compared to gG C (control).
And in spite of these lower levels it was accepted and rapidly cor-
rected with ephedrine if lowered less than 20%of baseline values.
These ﬁndings may be explained by the vasodilator effects
MgSO4 together with the sympatholytic effect of spinal
anesthesia.
Magnesium is a unique calcium antagonist as it can act on
most types of calcium channels in vascular smooth muscle and
as such would be expected to decrease intracellular calcium.
The decreased intracellular calcium inactivates the calmodu-
lin-dependent myosin light chain kinase activity which de-
creased contractility leading to arterial relaxation and this
lower peripheral and cerebral vascular resistance, relieve vaso-
spasm, and decrease arterial blood pressure [7].
In this study spinal anesthesia was used safely in preeclamp-
tic parturients.
These results went in agreement with Wallace and col-
leagues who performed a randomized trial investigating the ef-
fects of general anesthesia compared to combined epidural and
spinal anesthesia in severe pre-eclampsia and found that regio-
nal anesthesia is as safe as general anesthesia on patient’s
hemodynamic status [19]. Also the study by Hood and Curry,
who retrospectively recorded the effect of epidural and spinal
anesthesia in parturients with severe pre-eclampsia who were
scheduled for elective cesarean section [20].Several meta-analyses studies investigated the effect of gen-
eral anesthesia and neuroaxial (epidural, spinal) anesthesia on
cardiac complications and they found that overall mortality
was approximately one third less in patients in the neuroaxial
anesthesia group compared to those received general anesthe-
sia, similar beneﬁts were seen for noncardiac complications,
including thromboembolism and pneumonia [21].
9. Recommendations
It is recommended that further studies should include pregnant
females with severe pre-eclampsia and the use of more indica-
tors of myocardial injury other than serum cardiac troponin I
as S–T segment analysis of ECG can be employed.
10. Conclusion
Pretreatment with MgSO4 did not lower serum cardiac tropo-
nin I values in moderate pre-eclampsia undergoing elective
cesarean section using spinal anesthesia. It has vaso-dilatory
effect on blood vessel smooth muscles and control hyperten-
sion in pre-eclamptic parturients. Spinal anesthesia was not
associated with major myocardial adverse events and was as
acceptable and comparable as general anesthesia for cesarean
delivery.
Conﬂict of interest
No conﬂict of interest.
References
[1] Resnick L, Barbagallo M, Bardicef M, Bardicef O, Sorokin Y,
Evelhoch J, et al. Cellular-free magnesium depletion in brain and
muscle of normal and preeclamptic pregnancy. Hypertension
2004;44:322–6.
[2] Davison J. Pre-eclampsia as a multi-system disease. Adv Exp
Med Biol 1989;252:119–31.
[3] Sharma S, Jackson P, Makan J. Cardiac troponins. J Clin Pathol
2004;57(10):1025–6.
[4] Panteghini M. The measurement of cardiac markers: where
should we focus? Am J Clin Pathol 2002;118:354–6.
[5] Longo M, Jain V, Vedernikov YP, Facchinetti F, Saade GR,
Garﬁeld RE. Endothelium dependence and gestational
regulation of inhibition of vascular tone by magnesium sulfate
in rat aorta. Am J Obstet Gynecol 2001;184:971–8.
[6] Euser AG, Cipolla MJ. Resistance artery vasodilation to
magnesium sulfate during pregnancy and the postpartum state.
Am J Physiol Heart Circ Physiol 2005;288:H1521–5.
[7] Altura BM, Altura BT, Carella A, Gebrewold A, Murakawa T,
Nishio A. Mg2_–Ca2_ interaction in contractility of vascular
smooth muscle: Mg2_versus organic calcium channel blockers
on myogenic tone and agonist-induced responsiveness of blood
vessels. Can J Physiol Pharmacol 1987;65:729–45.
[8] Nelson SH, Suresh MS. Magnesium sulfate-induced relaxation
of uterine arteries from pregnant and non-pregnant patients.
Am J Obstet Gynecol 1991;164:1344–50.
[9] Ravn HB, Vissinger H, Kristensen SD, Wennmalm A, Thygesen
K, Husted SE. Magnesium inhibits platelet activity – an infusion
study in healthy volunteers. ThrombHaemostas 1996;75:939–44.
[10] Goldkrand JW, Fuentes AM. The relation of angiotensin-
converting enzyme to the pregnancy-induced hypertension–
preeclampsia syndrome. Am J Obstet Gynecol 1986;154:
792–800.
Effect of preoperative Mg sulfate infusion on serum cardiac troponin (cTn) in moderate preeclamptic undergoing elective 303[11] Khan F, Belch JJF, MacLeod M, Mires G. Changes in
endothelial function precedes the clinical disease in
women in whom preeclampsia develops. Hypertension 2005;
46:1123–8.
[12] Scardo JA, Hogg BB, Newman RB. Favorable hemodynamic
effects of magnesium sulfate in preeclampsia. Am J Obstet
Gynecol 1995;173(4):1249–53.
[13] Fleming SM, O’Gorman T, Finn J, Grimes H, Daly K,
Morrison JJ. Cardiac troponin I in preeclampsia and
gestational hypertension. BJOG 2000;107:1417–20.
[14] Nunes J. Cardiac troponin I in systemic diseases. Rev Port
Cardiol 2001;20:785–8.
[15] Atis A, Aydin Y, Basol E, Go¨ker N. Troponin I and
homocysteine levels in mild and severe preeclampsia. Clin
Experiment Obstet Gynecol 2010;37(1):21–3.
[16] Atalay C, Erden G, Turhan T. The effect of magnesium sulfate
treatment on serum cardiac troponin I levels in pre-eclamptic
women. Acta Obstet Gynaecol Scand 2005;84:617–21.[17] Chakraborti T, Mandal M, Mandal A, Das S, Ghosh S.
Protective role of magnesium in cardiovascular disease: a review.
Mol Cell Biochem 2002;238:163–79.
[18] Katus H, Schoeppenthau M, Tanzeem A, Bauer H, Saggau W,
Diederich K, et al. Non-invasive assessment of perioperative
myocardial cell damage by circulating cardiac troponin T. Brit
Heart J 1991;65:259–64.
[19] Wallace D, Leveno K, Cunningham F. Randomized comparison
of general and regional anaesthesia for caesarean delivery in
pregnancies complicated by severe pre-eclampsia. Obsetet
Gynecol 1995;86:193–9.
[20] Hood D, Curry R. Spinal versus epidural anaesthesia for
caesarean section in severely pre-eclampsia eclamptic patients: a
retrospective survey. Anaesthesiology 1999;90:1276–83.
[21] Rodgers A, Walker N, Schug S, McKee A, Kehlet H, van
Zundert A, et al. Reduction of postoperative mortality and
morbidity with epidural or spinal anaesthesia: results from
overview of randomized trials. BMJ 2000;321:1493.
